TG Therapeutics, Inc. (TGTX) shares rose 10.48 percent, gaining $3.84 to $40.48 on Tuesday after the company reported positive pharmacokinetic, pharmacodynamic, safety, and tolerability results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI compared with the currently approved intravenous version.
The stock is currently trading at $40.48, compared with its previous close of $36.64. During the session, it opened at $38.65 and traded between $37.96 and $40.69. Trading volume reached 1.02 million shares.
The company said the proprietary high-concentration, low-volume formulation was well tolerated and achieved sustained drug exposure. Data from the study support the quarterly and every-other-month dosing regimens currently being evaluated in an ongoing Phase 3 trial. Management noted that, if approved, subcutaneous BRIUMVI could become the first self-administered, at-home quarterly anti-CD20 therapy for multiple sclerosis patients.
TG Therapeutics shares have traded between $25.28 and $44.65 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.